Precision medicine analysis of heterogeneity in individual‐level treatment response to amyloid beta removal in early Alzheimer's disease

Donanemab in Early Symptomatic Alzheimer Disease

(2023) John R. Sims et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Neuropathologic Features of Antemortem Atrophy-Based Subtypes of Alzheimer Disease

(2022) Rosaleena Mohanty et al.   NEUROLOGY

Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable meta‐analysis

(2022) Menglan Pang et al.   Alzheimers & Dementia

Lecanemab in Early Alzheimer’s Disease

(2022) Christopher H. van Dyck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis

(2021) Giovanni E Ferreira et al.   BMJ-British Medical Journal

Disentangling heterogeneity in Alzheimer’s disease and related dementias using data-driven methods

(2020) Mohamad Habes et al.   BIOLOGICAL PSYCHIATRY

Biological subtypes of Alzheimer disease

(2020) Daniel Ferreira et al.   NEUROLOGY

Predicting Alzheimer's disease progression: Results from the TADPOLE Challenge

(2020) Razvan V. Marinescu et al.   Alzheimers & Dementia

Precision Medicine

(2019) Michael R. Kosorok et al.   Annual Review of Statistics and Its Application

A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis

(2019) Fabio Pellegrini et al.   Multiple Sclerosis Journal

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

(2019) Lisa Vermunt et al.   Alzheimers & Dementia

Subgroup identification in clinical trials via the predicted individual treatment effect

(2018) Nicolás M. Ballarini et al.   PLoS One

Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome

(2018) Kristina S Chen et al.   Therapeutics and Clinical Risk Management

Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects

(2018) David M Kent et al.   BMJ-British Medical Journal

ranger: A Fast Implementation of Random Forests for High Dimensional Data in C++ and R

(2017) Marvin N. Wright et al.   Journal of Statistical Software

Age, APOE and sex: Triad of risk of Alzheimer’s disease

(2016) Brandalyn C. Riedel et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Detecting treatment-covariate interactions using permutation methods

(2015) Rui Wang et al.   STATISTICS IN MEDICINE

Alzheimer's disease

(2015) Colin L. Masters et al.   Nature Reviews Disease Primers

Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints

(2014) B. Claggett et al.   BIOSTATISTICS

Effectively Selecting a Target Population for a Future Comparative Study

(2013) Lihui Zhao et al.   JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION

Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials

(2012) Jesse M. Cedarbaum et al.   Alzheimers & Dementia

Conditional Variable Importance for Random Forests

(2008) Carolin Strobl et al.   BMC BIOINFORMATICS